Nuveen Mortgage and Income Fund
Change company Symbol lookup
Select an option...
JLS Nuveen Mortgage and Income Fund
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
Go

Company profile

Nuveen Mortgage and Income Fund (the Fund), formerly Nuveen Mortgage Opportunity Term Fund, is a non-diversified, closed-end management investment company. The Fund's investment objective is to generate attractive total returns through opportunistic investments in mortgage-backed security (MBS). It seeks to achieve its investment objective by investing primarily in non-agency residential MBS and commercial MBS. The Fund may also invest up to 20% of its managed assets in other permitted investments, including cash and cash equivalents, the United States treasury securities, non-mortgage related asset-backed securities, inverse floating rate securities, municipal securities, interest rate futures, interest rate swaps and swaptions, non-MBS credit default swaps and other synthetic mortgage-related exposure, including equity investments in mortgage real estate investment trusts (REITs). The Fund's investment advisor is Nuveen Fund Advisors, LLC.

Closing Price
$21.02
Day's Change
-0.0666 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
21.10
Day's Low
21.01
Volume
(Heavy Day)
Volume:
13,970

10-day average volume:
8,258
13,970

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

11:34 pm ET March 21, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

.

On March 17, 2021, AbbVie issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic arthritis. The updated Prescription Drug User Fee Act (PDUFA) action date has been extended three months to late Q2 2021." The Company advised investors that "AbbVie recently received an information request from the FDA for an updated assessment of the benefit-risk profile for upadacitinib in psoriatic arthritis. AbbVie responded to the request and the FDA will require additional time for a full review of the submission."

On this news, AbbVie's stock price fell $5.80 per share, or 5.23%, to close at $105.04 per share on March 17, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/78136

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.